Propositions

GA4GH's Variant Annotation Specification defines a Proposition as an abstract entity representing a possible fact that may be trust or false.

Therapeutic Response

id	Type	Biomarkers	Cancer type	Therapies	Statements
prop:vtxr:0	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
prop:vtxr:1	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
prop:vtxr:2	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
prop:vtxr:3	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
prop:vtxr:4	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
prop:vtxr:5	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
prop:vtxr:6	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole
prop:vtxr:7	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
prop:vtxr:8	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
prop:vtxr:9	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
prop:vtxr:10	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
prop:vtxr:11	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
prop:vtxr:12	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib
prop:vtxr:13	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib
prop:vtxr:14	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib
prop:vtxr:15	Sensitivity	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
prop:vtxr:16	Sensitivity	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
prop:vtxr:17	Sensitivity	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
prop:vtxr:18	Sensitivity	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
prop:vtxr:19	Sensitivity	KRAS p.G12C	Non-Small Cell Lung Cancer	Adagrasib
prop:vtxr:20	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine
prop:vtxr:21	Sensitivity	EGFR Somatic variants	Non-Small Cell Lung Cancer	Afatinib
prop:vtxr:22	Sensitivity	v::ALK	Non-Small Cell Lung Cancer	Alectinib
prop:vtxr:23	Sensitivity	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
prop:vtxr:24	Sensitivity	HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
prop:vtxr:25	Sensitivity	ER positive, HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
prop:vtxr:26	Sensitivity	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
prop:vtxr:27	Sensitivity	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab
prop:vtxr:28	Sensitivity	PML::RARA	APL with PML-RARA	Arsenic trioxide
prop:vtxr:29	Sensitivity	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib
prop:vtxr:30	Sensitivity	ABL1 p.T315I, BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib
prop:vtxr:31	Sensitivity	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Atezolizumab
prop:vtxr:32	Sensitivity	PD-L1 >= 50%	Non-Small Cell Lung Cancer	Atezolizumab
prop:vtxr:33	Sensitivity	PD-L1 >= 10% TIIC	Non-Small Cell Lung Cancer	Atezolizumab
prop:vtxr:34	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
prop:vtxr:35	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Paclitaxel
prop:vtxr:36	Sensitivity	EGFR Somatic variants	Non-Small Cell Lung Cancer	Atezolizumab
prop:vtxr:37	Sensitivity	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab
prop:vtxr:38	Sensitivity	BRAF p.V600E	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib
prop:vtxr:39	Sensitivity	BRAF p.V600K	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib
prop:vtxr:40	Sensitivity	PDGFRA p.D842V	Gastrointestinal Stromal Tumor	Avapritinib
prop:vtxr:41	Sensitivity	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
prop:vtxr:42	Sensitivity	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib
prop:vtxr:43	Sensitivity	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib
prop:vtxr:45	Sensitivity	CD19 +	Acute Lymphoid Leukemia	Blinatumomab
prop:vtxr:46	Sensitivity	CD19 +, not BCR::ABL1	Acute Lymphoid Leukemia	Blinatumomab
prop:vtxr:47	Sensitivity	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib
prop:vtxr:48	Sensitivity	CD30 +	Anaplastic Large Cell Lymphoma	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
prop:vtxr:49	Sensitivity	CD30 +	Anaplastic Large Cell Lymphoma	Brentuximab vedotin
prop:vtxr:50	Sensitivity	v::ALK	Non-Small Cell Lung Cancer	Brigatinib
prop:vtxr:51	Sensitivity	HER2-positive	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine
prop:vtxr:52	Sensitivity	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:53	Sensitivity	HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:54	Sensitivity	ER positive, HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:55	Sensitivity	AKT1 Somatic variants, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:56	Sensitivity	AKT1 Somatic variants, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:57	Sensitivity	AKT1 Somatic variants, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:58	Sensitivity	AKT1 amplification, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:59	Sensitivity	AKT1 amplification, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:60	Sensitivity	AKT1 amplification, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:61	Sensitivity	ER positive, HER2-negative, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:62	Sensitivity	HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:63	Sensitivity	ER positive, HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:64	Sensitivity	ER positive, HER2-negative, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:65	Sensitivity	HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:66	Sensitivity	ER positive, HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:67	Sensitivity	ER positive, HER2-negative, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:68	Sensitivity	HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:69	Sensitivity	ER positive, HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:70	Sensitivity	ER positive, HER2-negative, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:71	Sensitivity	HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:72	Sensitivity	ER positive, HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:73	Sensitivity	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Capmatinib
prop:vtxr:74	Sensitivity	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Capmatinib
prop:vtxr:75	Sensitivity	Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed
prop:vtxr:76	Sensitivity	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR	Non-Small Cell Lung Cancer	Cemiplimab
prop:vtxr:77	Sensitivity	v::ALK	Non-Small Cell Lung Cancer	Ceritinib
prop:vtxr:78	Sensitivity	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan
prop:vtxr:79	Sensitivity	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
prop:vtxr:80	Sensitivity	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab
prop:vtxr:81	Sensitivity	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib
prop:vtxr:82	Sensitivity	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib
prop:vtxr:83	Sensitivity	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib
prop:vtxr:84	Sensitivity	v::ALK	Non-Small Cell Lung Cancer	Crizotinib
prop:vtxr:85	Sensitivity	v::ROS1	Non-Small Cell Lung Cancer	Crizotinib
prop:vtxr:86	Sensitivity	v::ALK	Anaplastic Large Cell Lymphoma	Crizotinib
prop:vtxr:87	Sensitivity	v::ALK	Inflammatory Myofibroblastic Tumor	Crizotinib
prop:vtxr:88	Sensitivity	BRAF p.V600E	Melanoma	Dabrafenib
prop:vtxr:89	Sensitivity	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
prop:vtxr:90	Sensitivity	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
prop:vtxr:91	Sensitivity	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
prop:vtxr:92	Sensitivity	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib
prop:vtxr:93	Sensitivity	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib
prop:vtxr:94	Sensitivity	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib
prop:vtxr:95	Sensitivity	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Dacomitinib
prop:vtxr:96	Sensitivity	EGFR p.L858R	Non-Small Cell Lung Cancer	Dacomitinib
prop:vtxr:97	Sensitivity	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib
prop:vtxr:98	Sensitivity	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib
prop:vtxr:99	Sensitivity	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib
prop:vtxr:100	Sensitivity	dMMR	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel
prop:vtxr:101	Sensitivity	MSI-H	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel
prop:vtxr:102	Sensitivity	dMMR	Endometrial Carcinoma	Dostarlimab
prop:vtxr:103	Sensitivity	dMMR	Any solid tumor	Dostarlimab
prop:vtxr:104	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed, Tremelimumab
prop:vtxr:105	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed, Tremelimumab
prop:vtxr:106	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Gemcitabine, Tremelimumab
prop:vtxr:107	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine, Tremelimumab
prop:vtxr:108	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
prop:vtxr:109	Sensitivity	dMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Paclitaxel
prop:vtxr:110	Sensitivity	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Elacestrant
prop:vtxr:111	Sensitivity	IDH2 p.R140Q	Acute Myeloid Leukemia	Enasidenib
prop:vtxr:112	Sensitivity	IDH2 p.R140L	Acute Myeloid Leukemia	Enasidenib
prop:vtxr:113	Sensitivity	IDH2 p.R140G	Acute Myeloid Leukemia	Enasidenib
prop:vtxr:114	Sensitivity	IDH2 p.R140W	Acute Myeloid Leukemia	Enasidenib
prop:vtxr:115	Sensitivity	IDH2 p.R172K	Acute Myeloid Leukemia	Enasidenib
prop:vtxr:116	Sensitivity	IDH2 p.R172M	Acute Myeloid Leukemia	Enasidenib
prop:vtxr:117	Sensitivity	IDH2 p.R172G	Acute Myeloid Leukemia	Enasidenib
prop:vtxr:118	Sensitivity	IDH2 p.R172S	Acute Myeloid Leukemia	Enasidenib
prop:vtxr:119	Sensitivity	IDH2 p.R172W	Acute Myeloid Leukemia	Enasidenib
prop:vtxr:120	Sensitivity	v::ROS1	Non-Small Cell Lung Cancer	Entrectinib
prop:vtxr:121	Sensitivity	v::NTRK1	Any solid tumor	Entrectinib
prop:vtxr:122	Sensitivity	v::NTRK2	Any solid tumor	Entrectinib
prop:vtxr:123	Sensitivity	v::NTRK3	Any solid tumor	Entrectinib
prop:vtxr:124	Sensitivity	FGFR3 p.R248C	Bladder Urothelial Carcinoma	Erdafitinib
prop:vtxr:125	Sensitivity	FGFR3 p.S249C	Bladder Urothelial Carcinoma	Erdafitinib
prop:vtxr:126	Sensitivity	FGFR3 p.G370C	Bladder Urothelial Carcinoma	Erdafitinib
prop:vtxr:127	Sensitivity	FGFR3 p.Y373C	Bladder Urothelial Carcinoma	Erdafitinib
prop:vtxr:128	Sensitivity	FGFR3::TACC3	Bladder Urothelial Carcinoma	Erdafitinib
prop:vtxr:129	Sensitivity	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib
prop:vtxr:130	Sensitivity	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib
prop:vtxr:131	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Everolimus, Exemestane
prop:vtxr:132	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane
prop:vtxr:133	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane
prop:vtxr:134	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant
prop:vtxr:135	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant
prop:vtxr:136	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant
prop:vtxr:137	Sensitivity	ER positive	Invasive Breast Carcinoma	Fulvestrant
prop:vtxr:138	Sensitivity	PR positive	Invasive Breast Carcinoma	Fulvestrant
prop:vtxr:139	Sensitivity	ER positive, PR positive	Invasive Breast Carcinoma	Fulvestrant
prop:vtxr:140	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
prop:vtxr:141	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
prop:vtxr:142	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
prop:vtxr:143	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
prop:vtxr:144	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
prop:vtxr:145	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
prop:vtxr:146	Sensitivity	FGFR2::v	Intrahepatic Cholangiocarcinoma	Futibatinib
prop:vtxr:147	Sensitivity	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Gefitinib
prop:vtxr:148	Sensitivity	EGFR p.L858R	Non-Small Cell Lung Cancer	Gefitinib
prop:vtxr:149	Sensitivity	CD33 +	Acute Lymphoid Leukemia	Gemtuzumab ozogamicin
prop:vtxr:150	Sensitivity	FLT3-ITD	Acute Myeloid Leukemia	Gilteritinib
prop:vtxr:151	Sensitivity	FLT3 p.D835Y	Acute Myeloid Leukemia	Gilteritinib
prop:vtxr:152	Sensitivity	FLT3 p.D835A	Acute Myeloid Leukemia	Gilteritinib
prop:vtxr:153	Sensitivity	FLT3 p.D835E	Acute Myeloid Leukemia	Gilteritinib
prop:vtxr:154	Sensitivity	FLT3 p.D835H	Acute Myeloid Leukemia	Gilteritinib
prop:vtxr:155	Sensitivity	FLT3 p.D835N	Acute Myeloid Leukemia	Gilteritinib
prop:vtxr:156	Sensitivity	FLT3 p.D835S	Acute Myeloid Leukemia	Gilteritinib
prop:vtxr:157	Sensitivity	FLT3 p.D835V	Acute Myeloid Leukemia	Gilteritinib
prop:vtxr:158	Sensitivity	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib
prop:vtxr:159	Sensitivity	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib
prop:vtxr:160	Sensitivity	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib
prop:vtxr:161	Sensitivity	PDGFRA rearrangements	Myelodysplastic Syndromes	Imatinib
prop:vtxr:162	Sensitivity	PDGFRB rearrangements	Myelodysplastic Syndromes	Imatinib
prop:vtxr:163	Sensitivity	not KIT p.D816V	Aggressive Systemic Mastocytosis	Imatinib
prop:vtxr:164	Sensitivity	FIP1L1::PDGFRA	Chronic Eosinophilic Leukemia, NOS	Imatinib
prop:vtxr:165	Sensitivity	CD117 +	Gastrointestinal Stromal Tumor	Imatinib
prop:vtxr:166	Sensitivity	FIP1L1::PDGFRA	Gastrointestinal Stromal Tumor	Imatinib
prop:vtxr:167	Sensitivity	FGFR2::v	Cholangiocarcinoma	Infigratinib
prop:vtxr:168	Sensitivity	CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin
prop:vtxr:169	Sensitivity	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
prop:vtxr:170	Sensitivity	pMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
prop:vtxr:171	Sensitivity	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab
prop:vtxr:172	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
prop:vtxr:173	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
prop:vtxr:174	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
prop:vtxr:175	Sensitivity	IDH1 p.R132C	Acute Myeloid Leukemia	Ivosidenib
prop:vtxr:176	Sensitivity	IDH1 p.R132G	Acute Myeloid Leukemia	Ivosidenib
prop:vtxr:177	Sensitivity	IDH1 p.R132H	Acute Myeloid Leukemia	Ivosidenib
prop:vtxr:178	Sensitivity	IDH1 p.R132L	Acute Myeloid Leukemia	Ivosidenib
prop:vtxr:179	Sensitivity	IDH1 p.R132S	Acute Myeloid Leukemia	Ivosidenib
prop:vtxr:180	Sensitivity	IDH1 p.R132C	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
prop:vtxr:181	Sensitivity	IDH1 p.R132G	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
prop:vtxr:182	Sensitivity	IDH1 p.R132H	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
prop:vtxr:183	Sensitivity	IDH1 p.R132L	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
prop:vtxr:184	Sensitivity	IDH1 p.R132S	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
prop:vtxr:185	Sensitivity	IDH1 p.R132C	Myelodysplastic Syndromes	Ivosidenib
prop:vtxr:186	Sensitivity	IDH1 p.R132G	Myelodysplastic Syndromes	Ivosidenib
prop:vtxr:187	Sensitivity	IDH1 p.R132H	Myelodysplastic Syndromes	Ivosidenib
prop:vtxr:188	Sensitivity	IDH1 p.R132L	Myelodysplastic Syndromes	Ivosidenib
prop:vtxr:189	Sensitivity	IDH1 p.R132S	Myelodysplastic Syndromes	Ivosidenib
prop:vtxr:190	Sensitivity	IDH1 p.R132C	Cholangiocarcinoma	Ivosidenib
prop:vtxr:191	Sensitivity	IDH1 p.R132G	Cholangiocarcinoma	Ivosidenib
prop:vtxr:192	Sensitivity	IDH1 p.R132H	Cholangiocarcinoma	Ivosidenib
prop:vtxr:193	Sensitivity	IDH1 p.R132L	Cholangiocarcinoma	Ivosidenib
prop:vtxr:194	Sensitivity	IDH1 p.R132S	Cholangiocarcinoma	Ivosidenib
prop:vtxr:195	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Lapatinib
prop:vtxr:196	Sensitivity	ER positive, HER2-positive	Invasive Breast Carcinoma	Lapatinib, Letrozole
prop:vtxr:197	Sensitivity	HER2-positive, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole
prop:vtxr:198	Sensitivity	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole
prop:vtxr:199	Sensitivity	v::NTRK1	Any solid tumor	Larotrectinib
prop:vtxr:200	Sensitivity	v::NTRK2	Any solid tumor	Larotrectinib
prop:vtxr:201	Sensitivity	v::NTRK3	Any solid tumor	Larotrectinib
prop:vtxr:202	Sensitivity	5q deletion	Myelodysplastic Syndromes	Lenalidomide
prop:vtxr:203	Sensitivity	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib
prop:vtxr:204	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Margetuximab
prop:vtxr:205	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Eribulin, Margetuximab
prop:vtxr:206	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Gemcitabine, Margetuximab
prop:vtxr:207	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Margetuximab, Vinorelbine
prop:vtxr:208	Sensitivity	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
prop:vtxr:209	Sensitivity	FLT3 p.D835Y	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
prop:vtxr:210	Sensitivity	FLT3 p.D835A	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
prop:vtxr:211	Sensitivity	FLT3 p.D835E	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
prop:vtxr:212	Sensitivity	FLT3 p.D835H	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
prop:vtxr:213	Sensitivity	FLT3 p.D835N	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
prop:vtxr:214	Sensitivity	FLT3 p.D835S	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
prop:vtxr:215	Sensitivity	FLT3 p.D835V	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
prop:vtxr:216	Sensitivity	FLT3 p.I836del	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
prop:vtxr:217	Sensitivity	CDK12 oncogenic variants	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
prop:vtxr:218	Sensitivity	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Mobocertinib
prop:vtxr:219	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Neratinib
prop:vtxr:220	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Neratinib
prop:vtxr:221	Sensitivity	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib
prop:vtxr:222	Sensitivity	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib
prop:vtxr:223	Sensitivity	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Niraparib
prop:vtxr:224	Sensitivity	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Niraparib
prop:vtxr:225	Sensitivity	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib
prop:vtxr:226	Sensitivity	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib
prop:vtxr:227	Sensitivity	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib
prop:vtxr:228	Sensitivity	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib
prop:vtxr:229	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel
prop:vtxr:230	Sensitivity	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab
prop:vtxr:231	Sensitivity	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
prop:vtxr:232	Sensitivity	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
prop:vtxr:233	Sensitivity	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
prop:vtxr:234	Sensitivity	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
prop:vtxr:235	Sensitivity	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
prop:vtxr:236	Sensitivity	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
prop:vtxr:237	Sensitivity	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
prop:vtxr:238	Sensitivity	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
prop:vtxr:239	Sensitivity	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
prop:vtxr:240	Sensitivity	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
prop:vtxr:241	Sensitivity	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
prop:vtxr:242	Sensitivity	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
prop:vtxr:243	Sensitivity	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
prop:vtxr:244	Sensitivity	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
prop:vtxr:245	Sensitivity	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
prop:vtxr:246	Sensitivity	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
prop:vtxr:247	Sensitivity	HRD	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
prop:vtxr:248	Sensitivity	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
prop:vtxr:249	Sensitivity	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
prop:vtxr:250	Sensitivity	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
prop:vtxr:251	Sensitivity	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
prop:vtxr:252	Sensitivity	HRD	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
prop:vtxr:253	Sensitivity	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
prop:vtxr:254	Sensitivity	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
prop:vtxr:255	Sensitivity	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
prop:vtxr:256	Sensitivity	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
prop:vtxr:257	Sensitivity	HRD	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
prop:vtxr:258	Sensitivity	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
prop:vtxr:259	Sensitivity	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
prop:vtxr:260	Sensitivity	BRCA1 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib
prop:vtxr:261	Sensitivity	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib
prop:vtxr:262	Sensitivity	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:263	Sensitivity	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:264	Sensitivity	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:265	Sensitivity	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:266	Sensitivity	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:267	Sensitivity	ATM pathogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:268	Sensitivity	ATM oncogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:269	Sensitivity	BARD1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:270	Sensitivity	BARD1 oncogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:271	Sensitivity	BRIP1 oncogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:272	Sensitivity	BRIP1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:273	Sensitivity	CDK12 pathogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:274	Sensitivity	CDK12 oncogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:275	Sensitivity	CHEK1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:276	Sensitivity	CHEK1 oncogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:277	Sensitivity	CHEK2 pathogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:278	Sensitivity	CHEK2 oncogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:279	Sensitivity	FANCL pathogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:280	Sensitivity	FANCL oncogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:281	Sensitivity	PALB2 pathogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:282	Sensitivity	PALB2 oncogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:283	Sensitivity	RAD51B pathogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:284	Sensitivity	RAD51B oncogenic variants	Prostate Adenocarcinoma	Talazoparib
prop:vtxr:285	Sensitivity	RAD51C pathogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:286	Sensitivity	RAD51C oncogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:287	Sensitivity	RAD51D pathogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:288	Sensitivity	RAD51D oncogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:289	Sensitivity	RAD54L pathogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:290	Sensitivity	RAD54L oncogenic variants	Prostate Adenocarcinoma	Olaparib
prop:vtxr:291	Sensitivity	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone
prop:vtxr:292	Sensitivity	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone
prop:vtxr:293	Sensitivity	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone
prop:vtxr:294	Sensitivity	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone
prop:vtxr:295	Sensitivity	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
prop:vtxr:296	Sensitivity	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
prop:vtxr:297	Sensitivity	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
prop:vtxr:298	Sensitivity	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
prop:vtxr:299	Sensitivity	IDH1 p.R132C	Acute Myeloid Leukemia	Olutasidenib
prop:vtxr:300	Sensitivity	IDH1 p.R132G	Acute Myeloid Leukemia	Olutasidenib
prop:vtxr:301	Sensitivity	IDH1 p.R132H	Acute Myeloid Leukemia	Olutasidenib
prop:vtxr:302	Sensitivity	IDH1 p.R132L	Acute Myeloid Leukemia	Olutasidenib
prop:vtxr:303	Sensitivity	IDH1 p.R132S	Acute Myeloid Leukemia	Olutasidenib
prop:vtxr:304	Sensitivity	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib
prop:vtxr:305	Sensitivity	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib
prop:vtxr:306	Sensitivity	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed
prop:vtxr:307	Sensitivity	EGFR p.L858R	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed
prop:vtxr:308	Sensitivity	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed
prop:vtxr:309	Sensitivity	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed
prop:vtxr:310	Sensitivity	EGFR p.T790M	Non-Small Cell Lung Cancer	Osimertinib
prop:vtxr:311	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Palbociclib
prop:vtxr:312	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib
prop:vtxr:313	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib
prop:vtxr:314	Sensitivity	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab
prop:vtxr:315	Sensitivity	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Panitumumab
prop:vtxr:316	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pembrolizumab, Pemetrexed
prop:vtxr:317	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed
prop:vtxr:318	Sensitivity	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
prop:vtxr:319	Sensitivity	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Pembrolizumab
prop:vtxr:320	Sensitivity	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab
prop:vtxr:321	Sensitivity	dMMR	Any solid tumor	Pembrolizumab
prop:vtxr:322	Sensitivity	MSI-H	Any solid tumor	Pembrolizumab
prop:vtxr:323	Sensitivity	dMMR	Colorectal Adenocarcinoma	Pembrolizumab
prop:vtxr:324	Sensitivity	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab
prop:vtxr:325	Sensitivity	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
prop:vtxr:326	Sensitivity	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab
prop:vtxr:327	Sensitivity	HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab
prop:vtxr:328	Sensitivity	HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Pembrolizumab
prop:vtxr:329	Sensitivity	PD-L1 (CPS) >= 10	Adenocarcinoma of the Gastroesophageal Junction	Pembrolizumab
prop:vtxr:330	Sensitivity	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Pembrolizumab
prop:vtxr:331	Sensitivity	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Cisplatin, Paclitaxel, Pembrolizumab
prop:vtxr:332	Sensitivity	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Pembrolizumab
prop:vtxr:333	Sensitivity	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
prop:vtxr:334	Sensitivity	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
prop:vtxr:335	Sensitivity	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Carboplatin, Paclitaxel, Pembrolizumab
prop:vtxr:336	Sensitivity	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Carboplatin, Paclitaxel, Pembrolizumab
prop:vtxr:337	Sensitivity	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
prop:vtxr:338	Sensitivity	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
prop:vtxr:339	Sensitivity	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Pembrolizumab
prop:vtxr:340	Sensitivity	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Pembrolizumab
prop:vtxr:341	Sensitivity	MSI-L	Endometrial Carcinoma	Lenvatinib, Pembrolizumab
prop:vtxr:342	Sensitivity	pMMR	Endometrial Carcinoma	Pembrolizumab
prop:vtxr:343	Sensitivity	MSI-H	Endometrial Carcinoma	Pembrolizumab
prop:vtxr:344	Sensitivity	TMB-H (>= 10 mutations / Mb)	Any solid tumor	Pembrolizumab
prop:vtxr:345	Sensitivity	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
prop:vtxr:346	Sensitivity	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Paclitaxel, Pembrolizumab
prop:vtxr:347	Sensitivity	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Carboplatin, Gemcitabine, Pembrolizumab
prop:vtxr:348	Sensitivity	FGFR2::v	Cholangiocarcinoma	Pemigatinib
prop:vtxr:349	Sensitivity	FGFR2 rearrangements	Cholangiocarcinoma	Pemigatinib
prop:vtxr:350	Sensitivity	FGFR1 rearrangements	Myeloid/Lymphoid Neoplasms	Pemigatinib
prop:vtxr:351	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab
prop:vtxr:352	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
prop:vtxr:353	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
prop:vtxr:354	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
prop:vtxr:355	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
prop:vtxr:356	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
prop:vtxr:357	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
prop:vtxr:358	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
prop:vtxr:359	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab
prop:vtxr:360	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
prop:vtxr:361	Sensitivity	BCR::ABL1	Acute Lymphoid Leukemia	Cytarabine, Dexamethasone, Methotrexate, Ponatinib, Prednisone, Vincristine
prop:vtxr:362	Sensitivity	ABL1 p.T315I, BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib
prop:vtxr:363	Sensitivity	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib
prop:vtxr:364	Sensitivity	v::RET	Non-Small Cell Lung Cancer	Pralsetinib
prop:vtxr:365	Sensitivity	v::RET	Papillary Thyroid Cancer	Pralsetinib
prop:vtxr:366	Sensitivity	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab
prop:vtxr:367	Sensitivity	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab
prop:vtxr:368	Sensitivity	v::ROS1	Non-Small Cell Lung Cancer	Repotrectinib
prop:vtxr:369	Sensitivity	v::NTRK1	Any solid tumor	Repotrectinib
prop:vtxr:370	Sensitivity	v::NTRK2	Any solid tumor	Repotrectinib
prop:vtxr:371	Sensitivity	v::NTRK3	Any solid tumor	Repotrectinib
prop:vtxr:372	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Ribociclib
prop:vtxr:373	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib
prop:vtxr:374	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib
prop:vtxr:375	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Ribociclib
prop:vtxr:376	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib
prop:vtxr:377	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib
prop:vtxr:378	Sensitivity	CD20 +	Non-Hodgkin Lymphoma	Rituximab
prop:vtxr:379	Sensitivity	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine
prop:vtxr:380	Sensitivity	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
prop:vtxr:381	Sensitivity	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Fludarabine, Mitoxantrone, Rituximab
prop:vtxr:382	Sensitivity	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
prop:vtxr:383	Sensitivity	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
prop:vtxr:384	Sensitivity	CD20 +	Burkitt Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
prop:vtxr:385	Sensitivity	CD20 +	Mature B-Cell Neoplasms	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
prop:vtxr:386	Sensitivity	CD20 +	Chronic Lymphocytic Leukemia	Cyclophosphamide, Fludarabine, Rituximab
prop:vtxr:387	Sensitivity	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib
prop:vtxr:388	Sensitivity	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib
prop:vtxr:389	Sensitivity	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib
prop:vtxr:390	Sensitivity	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib
prop:vtxr:391	Sensitivity	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
prop:vtxr:392	Sensitivity	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
prop:vtxr:393	Sensitivity	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
prop:vtxr:394	Sensitivity	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
prop:vtxr:395	Sensitivity	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib
prop:vtxr:396	Sensitivity	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib
prop:vtxr:397	Sensitivity	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib
prop:vtxr:398	Sensitivity	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib
prop:vtxr:399	Sensitivity	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Rucaparib
prop:vtxr:400	Sensitivity	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Rucaparib
prop:vtxr:401	Sensitivity	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Rucaparib
prop:vtxr:402	Sensitivity	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Rucaparib
prop:vtxr:403	Sensitivity	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Sacituzumab govitecan
prop:vtxr:404	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Sacituzumab govitecan
prop:vtxr:405	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan
prop:vtxr:406	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan
prop:vtxr:407	Sensitivity	v::RET	Non-Small Cell Lung Cancer	Selpercatinib
prop:vtxr:408	Sensitivity	RET oncogenic variants	Medullary Thyroid Cancer	Selpercatinib
prop:vtxr:409	Sensitivity	v::RET	Anaplastic Thyroid Cancer	Selpercatinib
prop:vtxr:410	Sensitivity	v::RET	Any solid tumor	Selpercatinib
prop:vtxr:411	Sensitivity	KRAS p.G12C	Non-Small Cell Lung Cancer	Sotorasib
prop:vtxr:412	Sensitivity	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
prop:vtxr:413	Sensitivity	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
prop:vtxr:414	Sensitivity	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Tepotinib
prop:vtxr:415	Sensitivity	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Tepotinib
prop:vtxr:416	Sensitivity	BRAF p.V600E	Melanoma	Trametinib
prop:vtxr:417	Sensitivity	BRAF p.V600K	Melanoma	Trametinib
prop:vtxr:418	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
prop:vtxr:419	Sensitivity	HER2-positive	Gastrointestinal Stromal Tumor	Trastuzumab
prop:vtxr:420	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan
prop:vtxr:421	Sensitivity	HER2-low	Invasive Breast Carcinoma	Trastuzumab deruxtecan
prop:vtxr:422	Sensitivity	ERBB2 activating variants	Non-Small Cell Lung Cancer	Trastuzumab deruxtecan
prop:vtxr:423	Sensitivity	HER2-positive	Adenocarcinoma of the Gastroesophageal Junction	Trastuzumab deruxtecan
prop:vtxr:424	Sensitivity	HER2-positive	Any solid tumor	Trastuzumab deruxtecan
prop:vtxr:425	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Trastuzumab, Tucatinib
prop:vtxr:426	Sensitivity	BRAF p.V600E	Melanoma	Vemurafenib
prop:vtxr:427	Sensitivity	BRAF p.V600E	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib
prop:vtxr:428	Sensitivity	BRAF p.V600K	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib
prop:vtxr:429	Sensitivity	EZH2 p.Y646N	Follicular Lymphoma	Tazemetostat
prop:vtxr:430	Sensitivity	EZH2 p.Y646F	Follicular Lymphoma	Tazemetostat
prop:vtxr:431	Sensitivity	EZH2 p.Y646H	Follicular Lymphoma	Tazemetostat
prop:vtxr:432	Sensitivity	EZH2 p.Y646S	Follicular Lymphoma	Tazemetostat
prop:vtxr:433	Sensitivity	EZH2 p.Y646C	Follicular Lymphoma	Tazemetostat
prop:vtxr:434	Sensitivity	EZH2 p.A682G	Follicular Lymphoma	Tazemetostat
prop:vtxr:435	Sensitivity	EZH2 p.A692V	Follicular Lymphoma	Tazemetostat
prop:vtxr:436	Sensitivity	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:437	Sensitivity	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:438	Sensitivity	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:439	Sensitivity	ATM pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:440	Sensitivity	ATM oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:441	Sensitivity	ATR oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:442	Sensitivity	CDK12 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:443	Sensitivity	ATR pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:444	Sensitivity	FANCA oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:445	Sensitivity	CHEK2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:446	Sensitivity	CHEK2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:447	Sensitivity	FANCA pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:448	Sensitivity	MLH1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:449	Sensitivity	PALB2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:450	Sensitivity	PALB2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:451	Sensitivity	MLH1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:452	Sensitivity	MRE11 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:453	Sensitivity	RAD51C pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:454	Sensitivity	RAD51C oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:455	Sensitivity	MRE11 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:456	Sensitivity	NBN oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:457	Sensitivity	NBN pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:458	Sensitivity	TSC1 oncogenic variants	Renal Angiomyolipoma	Everolimus
prop:vtxr:459	Sensitivity	TSC2 oncogenic variants	Renal Angiomyolipoma	Everolimus
prop:vtxr:460	Sensitivity	TSC1 oncogenic variants	Subependymal Giant Cell Astrocytoma	Everolimus
prop:vtxr:461	Sensitivity	TSC2 oncogenic variants	Subependymal Giant Cell Astrocytoma	Everolimus
prop:vtxr:462	Sensitivity	CDK12 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
prop:vtxr:463	Sensitivity	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
prop:vtxr:464	Sensitivity	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
prop:vtxr:465	Sensitivity	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
prop:vtxr:466	Sensitivity	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
prop:vtxr:467	Sensitivity	FOLR1 positive	Ovarian Epithelial Tumor	Mirvetuximab soravtansine
prop:vtxr:468	Sensitivity	FOLR1 positive	High-Grade Serous Fallopian Tube Cancer	Mirvetuximab soravtansine
prop:vtxr:469	Sensitivity	FOLR1 positive	Peritoneal Serous Carcinoma	Mirvetuximab soravtansine
prop:vtxr:470	Sensitivity	BRAF rearrangements	Low-Grade Glioma, NOS	Tovorafenib
prop:vtxr:471	Sensitivity	v::BRAF	Low-Grade Glioma, NOS	Tovorafenib
prop:vtxr:472	Sensitivity	BRAF p.V600E	Low-Grade Glioma, NOS	Tovorafenib
prop:vtxr:473	Sensitivity	BRAF p.V600K	Low-Grade Glioma, NOS	Tovorafenib
prop:vtxr:474	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Paclitaxel
prop:vtxr:475	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine
prop:vtxr:476	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed
prop:vtxr:477	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed
prop:vtxr:478	Sensitivity	KRAS p.G12C	Colorectal Adenocarcinoma	Adagrasib, Cetuximab
prop:vtxr:479	Sensitivity	IDH1 p.R132C	Astrocytoma	Vorasidenib
prop:vtxr:480	Sensitivity	IDH1 p.R132G	Astrocytoma	Vorasidenib
prop:vtxr:481	Sensitivity	IDH1 p.R132H	Astrocytoma	Vorasidenib
prop:vtxr:482	Sensitivity	IDH1 p.R132L	Astrocytoma	Vorasidenib
prop:vtxr:483	Sensitivity	IDH1 p.R132S	Astrocytoma	Vorasidenib
prop:vtxr:484	Sensitivity	IDH2 p.R172K	Astrocytoma	Vorasidenib
prop:vtxr:485	Sensitivity	IDH2 p.R172M	Astrocytoma	Vorasidenib
prop:vtxr:486	Sensitivity	IDH2 p.R172G	Astrocytoma	Vorasidenib
prop:vtxr:487	Sensitivity	IDH2 p.R172S	Astrocytoma	Vorasidenib
prop:vtxr:488	Sensitivity	IDH2 p.R172W	Astrocytoma	Vorasidenib
prop:vtxr:489	Sensitivity	IDH1 p.R132C	Oligodendroglioma	Vorasidenib
prop:vtxr:490	Sensitivity	IDH1 p.R132G	Oligodendroglioma	Vorasidenib
prop:vtxr:491	Sensitivity	IDH1 p.R132H	Oligodendroglioma	Vorasidenib
prop:vtxr:492	Sensitivity	IDH1 p.R132L	Oligodendroglioma	Vorasidenib
prop:vtxr:493	Sensitivity	IDH1 p.R132S	Oligodendroglioma	Vorasidenib
prop:vtxr:494	Sensitivity	IDH2 p.R172K	Oligodendroglioma	Vorasidenib
prop:vtxr:495	Sensitivity	IDH2 p.R172M	Oligodendroglioma	Vorasidenib
prop:vtxr:496	Sensitivity	IDH2 p.R172G	Oligodendroglioma	Vorasidenib
prop:vtxr:497	Sensitivity	IDH2 p.R172S	Oligodendroglioma	Vorasidenib
prop:vtxr:498	Sensitivity	IDH2 p.R172W	Oligodendroglioma	Vorasidenib
prop:vtxr:499	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib
prop:vtxr:500	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib
prop:vtxr:501	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib
prop:vtxr:502	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib
prop:vtxr:503	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib
prop:vtxr:504	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib
prop:vtxr:505	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed
prop:vtxr:506	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab
prop:vtxr:507	Sensitivity	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
prop:vtxr:508	Sensitivity	MSI-H	Colorectal Adenocarcinoma	Nivolumab
prop:vtxr:509	Sensitivity	dMMR	Colorectal Adenocarcinoma	Nivolumab
prop:vtxr:510	Sensitivity	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib
prop:vtxr:511	Sensitivity	HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib
prop:vtxr:512	Sensitivity	ER positive, HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib
prop:vtxr:513	Sensitivity	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Oxaliplatin, Zolbetuximab
prop:vtxr:514	Sensitivity	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Zolbetuximab
prop:vtxr:515	Sensitivity	HER2-positive	Intraductal Papillary Neoplasm of the Bile Duct	Zanidatamab
prop:vtxr:516	Sensitivity	HER2-positive	Intracholecystic Papillary Neoplasm	Zanidatamab
prop:vtxr:517	Sensitivity	HER2-positive	Cholangiocarcinoma	Zanidatamab
prop:vtxr:518	Sensitivity	v::NRG1	Non-Small Cell Lung Cancer	Zenocutuzumab
prop:vtxr:519	Sensitivity	v::NRG1	Pancreatic Adenocarcinoma	Zenocutuzumab
prop:vtxr:520	Sensitivity	v::ALK	Non-Small Cell Lung Cancer	Ensartinib
prop:vtxr:521	Sensitivity	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
prop:vtxr:522	Sensitivity	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Asciminib
prop:vtxr:528	Sensitivity	t(KMT2A;v)	Acute Lymphoid Leukemia	Revumenib
prop:vtxr:529	Sensitivity	t(KMT2A;v)	Acute Myeloid Leukemia	Revumenib
prop:vtxr:530	Sensitivity	t(KMT2A;v)	Burkitt Lymphoma	Revumenib
prop:vtxr:531	Sensitivity	t(KMT2A;v)	Acute Leukemias of Ambiguous Lineage	Revumenib
prop:vtxr:532	Sensitivity	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin, Dacarbazine, Doxorubicin, Vinblastine
prop:vtxr:533	Sensitivity	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin
prop:vtxr:534	Sensitivity	CD30 +	Cutaneous T-cell Lymphoma	Brentuximab vedotin
prop:vtxr:537	Sensitivity	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
prop:vtxr:538	Sensitivity	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
prop:vtxr:539	Sensitivity	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
prop:vtxr:540	Sensitivity	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
prop:vtxr:541	Sensitivity	EGFR p.L858R	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib
prop:vtxr:542	Sensitivity	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib
prop:vtxr:543	Sensitivity	CD22 +, not BCR::ABL1	Acute Lymphoid Leukemia	Inotuzumab ozogamicin
prop:vtxr:545	Sensitivity	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Bosutinib
prop:vtxr:546	Sensitivity	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Dordaviprone
prop:vtxr:547	Sensitivity	v::RET	Medullary Thyroid Cancer	Vandetanib
prop:vtxr:548	Sensitivity	EGFR activating variants	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab
prop:vtxr:549	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
prop:vtxr:550	Sensitivity	ERBB2 amplification	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
prop:vtxr:551	Sensitivity	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab deruxtecan
prop:vtxr:552	Sensitivity	ERBB2 amplification	Non-Small Cell Lung Cancer	Trastuzumab deruxtecan
prop:vtxr:553	Sensitivity	ERBB2 amplification	Adenocarcinoma of the Gastroesophageal Junction	Trastuzumab deruxtecan
prop:vtxr:554	Sensitivity	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab
prop:vtxr:555	Sensitivity	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
prop:vtxr:556	Sensitivity	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Oxaliplatin
prop:vtxr:559	Sensitivity	EGFR activating variants	Non-Small Cell Lung Cancer	Gefitinib
prop:vtxr:560	Sensitivity	EGFR activating variants	Non-Small Cell Lung Cancer	Afatinib
prop:vtxr:561	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
prop:vtxr:562	Sensitivity	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
prop:vtxr:563	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab
prop:vtxr:564	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab
prop:vtxr:565	Sensitivity	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab
prop:vtxr:566	Sensitivity	ERBB2 amplification	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
prop:vtxr:567	Sensitivity	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
prop:vtxr:568	Sensitivity	ERBB2 amplification	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab
prop:vtxr:569	Sensitivity	ERBB2 amplification	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab
prop:vtxr:570	Sensitivity	HER2-positive	Esophagogastric Adenocarcinoma	Capecitabine, Cisplatin, Trastuzumab
prop:vtxr:571	Sensitivity	HER2-positive	Esophagogastric Adenocarcinoma	Cisplatin, Fluorouracil, Trastuzumab
prop:vtxr:572	Sensitivity	ERBB2 amplification	Esophagogastric Adenocarcinoma	Capecitabine, Cisplatin, Trastuzumab
prop:vtxr:573	Sensitivity	ERBB2 amplification	Esophagogastric Adenocarcinoma	Cisplatin, Fluorouracil, Trastuzumab
prop:vtxr:578	Sensitivity	not BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib
prop:vtxr:579	Sensitivity	not BCR::ABL1	Acute Lymphoid Leukemia	Imatinib
prop:vtxr:580	Sensitivity	PDGFRA rearrangements	Myeloproliferative Neoplasm	Imatinib
prop:vtxr:581	Sensitivity	PDGFRB rearrangements	Myeloproliferative Neoplasm	Imatinib
prop:vtxr:582	Sensitivity	not BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib
prop:vtxr:583	Sensitivity	ABL1 p.T315I, not BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib
prop:vtxr:584	Sensitivity	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Durvalumab
prop:vtxr:585	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Tremelimumab
prop:vtxr:586	Sensitivity	pMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Olaparib, Paclitaxel
prop:vtxr:587	Sensitivity	MSI-H	Endometrial Carcinoma	Dostarlimab
prop:vtxr:588	Sensitivity	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
prop:vtxr:589	Sensitivity	CD274 amplification, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
prop:vtxr:592	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Pembrolizumab
prop:vtxr:593	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Gemcitabine, Pembrolizumab
prop:vtxr:594	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Paclitaxel, Pembrolizumab
prop:vtxr:595	Sensitivity	PD-L1 (CPS) >= 10	Bladder Urothelial Carcinoma	Pembrolizumab
prop:vtxr:596	Sensitivity	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Carboplatin, Fluorouracil, Pembrolizumab
prop:vtxr:597	Sensitivity	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Pembrolizumab
prop:vtxr:598	Sensitivity	PD-L1 >= 50%	Head and Neck Squamous Cell Carcinoma	Pembrolizumab
prop:vtxr:599	Sensitivity	dMMR	Endometrial Carcinoma	Pembrolizumab
prop:vtxr:600	Sensitivity	MSI-H	Esophagogastric Adenocarcinoma	Pembrolizumab
prop:vtxr:601	Sensitivity	dMMR	Esophagogastric Adenocarcinoma	Pembrolizumab
prop:vtxr:602	Sensitivity	MSI-H	Gastrointestinal Stromal Tumor	Pembrolizumab
prop:vtxr:603	Sensitivity	dMMR	Gastrointestinal Stromal Tumor	Pembrolizumab
prop:vtxr:604	Sensitivity	MSI-H	Cholangiocarcinoma	Pembrolizumab
prop:vtxr:605	Sensitivity	dMMR	Cholangiocarcinoma	Pembrolizumab
prop:vtxr:606	Sensitivity	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Cisplatin, Fluorouracil, Pembrolizumab
prop:vtxr:607	Sensitivity	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Carboplatin, Fluorouracil, Pembrolizumab
prop:vtxr:608	Sensitivity	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Pembrolizumab
prop:vtxr:609	Sensitivity	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Nab-paclitaxel, Pembrolizumab
prop:vtxr:610	Sensitivity	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Carboplatin, Fluorouracil, Pembrolizumab, Trastuzumab
prop:vtxr:611	Sensitivity	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab
prop:vtxr:612	Sensitivity	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Carboplatin, Fluorouracil, Pembrolizumab
prop:vtxr:613	Sensitivity	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab emtansine
prop:vtxr:618	Sensitivity	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Cemiplimab
prop:vtxr:619	Sensitivity	PD-L1 >= 1%, Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed
prop:vtxr:620	Sensitivity	pMMR	Endometrial Carcinoma	Durvalumab, Olaparib
prop:vtxr:621	Sensitivity	FGFR2 rearrangements	Cholangiocarcinoma	Futibatinib
prop:vtxr:622	Sensitivity	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
prop:vtxr:624	Sensitivity	CD20 +	Diffuse Large B-Cell Lymphoma	Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine
prop:vtxr:625	Sensitivity	CD20 +	Non-Hodgkin Lymphoma	Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine
prop:vtxr:626	Sensitivity	CD20 +	Burkitt Lymphoma	Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine
prop:vtxr:627	Sensitivity	BRAF p.V600K	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
prop:vtxr:628	Sensitivity	CD33 +	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Gemtuzumab ozogamicin
prop:vtxr:629	Sensitivity	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib
prop:vtxr:630	Sensitivity	ER positive, HER2-positive	Invasive Breast Carcinoma	Neratinib
prop:vtxr:631	Sensitivity	HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib
prop:vtxr:632	Sensitivity	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib
prop:vtxr:633	Sensitivity	ER positive, ERBB2 amplification	Invasive Breast Carcinoma	Neratinib
prop:vtxr:634	Sensitivity	ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib
prop:vtxr:638	Sensitivity	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel
prop:vtxr:639	Sensitivity	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Pemetrexed
prop:vtxr:640	Sensitivity	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab
prop:vtxr:641	Sensitivity	PD-L1 >= 1%	Bladder Urothelial Carcinoma	Nivolumab
prop:vtxr:642	Sensitivity	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Ipilimumab, Nivolumab
prop:vtxr:643	Sensitivity	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Nivolumab
prop:vtxr:644	Sensitivity	HER2-negative, PD-L1 (CPS) >= 5	Esophageal Adenocarcinoma	Fluorouracil, Nivolumab, Oxaliplatin
prop:vtxr:645	Sensitivity	HER2-negative, PD-L1 (CPS) >= 5	Esophageal Adenocarcinoma	Nivolumab, Oxaliplatin
prop:vtxr:646	Sensitivity	HER2-negative, PD-L1 (CPS) >= 5	Esophagogastric Adenocarcinoma	Fluorouracil, Nivolumab, Oxaliplatin
prop:vtxr:647	Sensitivity	HER2-negative, PD-L1 (CPS) >= 5	Esophagogastric Adenocarcinoma	Nivolumab, Oxaliplatin
prop:vtxr:648	Sensitivity	HER2-negative, PD-L1 (CPS) >= 5	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Nivolumab, Oxaliplatin
prop:vtxr:649	Sensitivity	HER2-negative, PD-L1 (CPS) >= 5	Adenocarcinoma of the Gastroesophageal Junction	Nivolumab, Oxaliplatin
prop:vtxr:650	Sensitivity	PD-L1 < 1%	Melanoma	Nivolumab, Relatlimab
prop:vtxr:651	Sensitivity	FGFR2::v	Cholangiocarcinoma	Elacestrant
prop:vtxr:652	Sensitivity	FGFR2 rearrangements	Cholangiocarcinoma	Elacestrant
prop:vtxr:653	Sensitivity	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
prop:vtxr:654	Sensitivity	HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
prop:vtxr:655	Sensitivity	ER positive, HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
prop:vtxr:656	Sensitivity	v::RET	Papillary Thyroid Cancer	Selpercatinib
prop:vtxr:657	Sensitivity	RET p.M918T	Medullary Thyroid Cancer	Selpercatinib
prop:vtxr:658	Sensitivity	5q deletion	Myeloproliferative Neoplasm	Lenalidomide
prop:vtxr:659	Sensitivity	not BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib
prop:vtxr:660	Sensitivity	BRAF p.V600E	High-Grade Glioma, NOS	Dabrafenib, Trametinib
prop:vtxr:661	Sensitivity	not BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib
prop:vtxr:662	Sensitivity	not BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib
prop:vtxr:663	Sensitivity	BRAF p.V600K	Melanoma	Dabrafenib
prop:vtxr:664	Sensitivity	EGFR activating variants	Non-Small Cell Lung Cancer	Osimertinib
prop:vtxr:665	Sensitivity	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib
prop:vtxr:666	Sensitivity	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib
prop:vtxr:667	Sensitivity	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib
prop:vtxr:668	Sensitivity	EGFR p.L858R	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib
prop:vtxr:669	Sensitivity	EGFR activating variants	Non-Small Cell Lung Cancer	Erlotinib
prop:vtxr:670	Sensitivity	not BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib
prop:vtxr:671	Sensitivity	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab
prop:vtxr:672	Sensitivity	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
prop:vtxr:673	Sensitivity	EGFR Somatic variants	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
prop:vtxr:674	Sensitivity	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
prop:vtxr:675	Sensitivity	Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel
prop:vtxr:676	Sensitivity	Wild type ALK	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel
prop:vtxr:677	Sensitivity	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel
prop:vtxr:678	Sensitivity	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
prop:vtxr:679	Sensitivity	ER negative, HER2-negative, PD-L1 >= 1%, PR negative	Invasive Breast Carcinoma	Atezolizumab, Nab-paclitaxel
prop:vtxr:685	Sensitivity	ER positive, HER2-positive, PR negative	Invasive Breast Carcinoma	Lapatinib, Trastuzumab
prop:vtxr:687	Sensitivity	ERBB2 amplification	Invasive Breast Carcinoma	Capecitabine, Lapatinib
prop:vtxr:688	Sensitivity	ER positive, ERBB2 amplification, PR negative	Invasive Breast Carcinoma	Lapatinib, Trastuzumab
prop:vtxr:689	Sensitivity	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole
prop:vtxr:690	Sensitivity	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab
prop:vtxr:691	Sensitivity	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Irinotecan, Panitumumab
prop:vtxr:692	Sensitivity	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Panitumumab
prop:vtxr:693	Sensitivity	TP53 Somatic variants	Chronic Lymphocytic Leukemia	Venetoclax
prop:vtxr:694	Sensitivity	TP53 deletion	Chronic Lymphocytic Leukemia	Venetoclax
prop:vtxr:695	Sensitivity	not 17p deletion	Chronic Lymphocytic Leukemia	Venetoclax
prop:vtxr:696	Sensitivity	Wild type TP53	Chronic Lymphocytic Leukemia	Venetoclax
prop:vtxr:708	Sensitivity	EGFR activating variants	Non-Small Cell Lung Cancer	Dacomitinib
prop:vtxr:711	Sensitivity	BRAF p.V600K	Melanoma	Vemurafenib
prop:vtxr:712	Sensitivity	TP53 deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
prop:vtxr:713	Sensitivity	TP53 Somatic variants	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
prop:vtxr:714	Sensitivity	not 17p deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
prop:vtxr:715	Sensitivity	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pemetrexed, Tislelizumab
prop:vtxr:716	Sensitivity	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pemetrexed, Tislelizumab
prop:vtxr:717	Sensitivity	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:718	Sensitivity	ER positive, HER2-negative, PIK3CA amplification	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
prop:vtxr:719	Sensitivity	FGFR2::BICC1	Bladder Urothelial Carcinoma	Erdafitinib
prop:vtxr:720	Sensitivity	FGFR2::CASP7	Bladder Urothelial Carcinoma	Erdafitinib
prop:vtxr:721	Sensitivity	FGFR3::BAIAP2L1	Bladder Urothelial Carcinoma	Erdafitinib
prop:vtxr:741	Sensitivity	TP53 Somatic variants	Chronic Lymphocytic Leukemia	Zanubrutinib
prop:vtxr:742	Sensitivity	TP53 deletion	Chronic Lymphocytic Leukemia	Zanubrutinib
prop:vtxr:743	Sensitivity	not 17p deletion	Chronic Lymphocytic Leukemia	Zanubrutinib
prop:vtxr:744	Sensitivity	TP53 Somatic variants	Chronic Lymphocytic Leukemia	Acalabrutinib
prop:vtxr:745	Sensitivity	TP53 deletion	Chronic Lymphocytic Leukemia	Acalabrutinib
prop:vtxr:746	Sensitivity	not 17p deletion	Chronic Lymphocytic Leukemia	Acalabrutinib
prop:vtxr:747	Sensitivity	TP53 Somatic variants	Chronic Lymphocytic Leukemia	Ibrutinib
prop:vtxr:748	Sensitivity	TP53 deletion	Chronic Lymphocytic Leukemia	Ibrutinib
prop:vtxr:749	Sensitivity	not 17p deletion	Chronic Lymphocytic Leukemia	Ibrutinib
prop:vtxr:757	Sensitivity	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin, Cisplatin, Cytarabine, Etoposide
prop:vtxr:758	Sensitivity	CD33 +	Acute Lymphoid Leukemia	Cytarabine, Daunorubicin, Gemtuzumab ozogamicin
prop:vtxr:759	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab
prop:vtxr:760	Sensitivity	CD30 +, HER2-negative	Hodgkin Lymphoma	Brentuximab vedotin, Carboplatin, Etoposide, Ifosfamide
prop:vtxr:761	Sensitivity	HER2-negative, PD-L1 (CPS) >= 10	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab
prop:vtxr:762	Sensitivity	HER2-negative, PD-L1 (CPS) >= 10	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Oxaliplatin, Pembrolizumab
prop:vtxr:763	Sensitivity	not BCR::ABL1	Acute Lymphoid Leukemia	Blinatumomab
prop:vtxr:764	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab
prop:vtxr:765	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab, Vinorelbine
prop:vtxr:766	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab
prop:vtxr:767	Sensitivity	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Gemcitabine, Nivolumab
prop:vtxr:768	Sensitivity	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed
prop:vtxr:769	Sensitivity	HER2-negative	Invasive Breast Carcinoma	Bevacizumab, Paclitaxel
prop:vtxr:770	Sensitivity	EGFR activating variants	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib
prop:vtxr:771	Sensitivity	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Capecitabine
prop:vtxr:772	Sensitivity	ER positive	Invasive Breast Carcinoma	Tamoxifen
prop:vtxr:773	Sensitivity	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
prop:vtxr:774	Sensitivity	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole
prop:vtxr:775	Sensitivity	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
prop:vtxr:776	Sensitivity	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
prop:vtxr:777	Sensitivity	ER positive, ERBB2 amplification	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
prop:vtxr:778	Sensitivity	ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
prop:vtxr:782	Sensitivity	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel
prop:vtxr:783	Sensitivity	ER negative	Invasive Breast Carcinoma	Fulvestrant
prop:vtxr:784	Sensitivity	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole
prop:vtxr:785	Sensitivity	ER positive	Invasive Breast Carcinoma	Letrozole
prop:vtxr:786	Sensitivity	PR positive	Invasive Breast Carcinoma	Letrozole
prop:vtxr:787	Sensitivity	ER positive, PR positive	Invasive Breast Carcinoma	Exemestane
prop:vtxr:788	Sensitivity	ER positive	Invasive Breast Carcinoma	Exemestane
prop:vtxr:789	Sensitivity	PR positive	Invasive Breast Carcinoma	Exemestane
prop:vtxr:790	Sensitivity	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Gemcitabine
prop:vtxr:791	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Trastuzumab
prop:vtxr:792	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
prop:vtxr:793	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane
prop:vtxr:794	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
prop:vtxr:796	Sensitivity	EGFR positive, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab
prop:vtxr:797	Sensitivity	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan
prop:vtxr:798	Sensitivity	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
prop:vtxr:800	Sensitivity	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Nivolumab, Oxaliplatin
prop:vtxr:801	Sensitivity	TP53 Somatic variants	Chronic Lymphocytic Leukemia	Idelalisib, Ofatumumab
prop:vtxr:802	Sensitivity	TP53 deletion	Chronic Lymphocytic Leukemia	Idelalisib, Ofatumumab
prop:vtxr:803	Sensitivity	not 17p deletion	Chronic Lymphocytic Leukemia	Idelalisib, Ofatumumab
prop:vtxr:804	Sensitivity	FLT3-ITD	Acute Myeloid Leukemia	Midostaurin
prop:vtxr:808	Sensitivity	CD20 +	Non-Hodgkin Lymphoma	Bendamustine, Rituximab
prop:vtxr:809	Sensitivity	CD20 +	Non-Hodgkin Lymphoma	Cisplatin, Cytarabine, Rituximab
prop:vtxr:810	Sensitivity	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine
prop:vtxr:811	Sensitivity	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine
prop:vtxr:812	Sensitivity	CD20 +	Non-Hodgkin Lymphoma	Carboplatin, Etoposide, Ifosfamide, Rituximab
prop:vtxr:813	Sensitivity	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vinorelbine
prop:vtxr:814	Sensitivity	CD20 +	Diffuse Large B-Cell Lymphoma	Gemcitabine, Oxaliplatin, Rituximab
prop:vtxr:815	Sensitivity	CD20 +	Non-Hodgkin Lymphoma	Gemcitabine, Oxaliplatin, Rituximab
prop:vtxr:816	Sensitivity	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine
prop:vtxr:817	Sensitivity	CD30 +	Hodgkin Lymphoma	Bendamustine, Brentuximab vedotin
prop:vtxr:818	Sensitivity	CD20 +	Follicular Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine
prop:vtxr:819	Sensitivity	CD20 +	Follicular Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
prop:vtxr:820	Sensitivity	CD20 +	Follicular Lymphoma	Chlorambucil, Mitoxantrone, Prednisolone, Rituximab
prop:vtxr:821	Sensitivity	CD20 +	Follicular Lymphoma	Cyclophosphamide, Doxorubicin, Etoposide, Interferon Alpha, Prednisolone, Rituximab
prop:vtxr:822	Sensitivity	CD20 +	Follicular Lymphoma	Rituximab
prop:vtxr:824	Sensitivity	ER positive	Invasive Breast Carcinoma	Anastrozole
prop:vtxr:825	Sensitivity	PR positive	Invasive Breast Carcinoma	Anastrozole
prop:vtxr:826	Sensitivity	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole
prop:vtxr:827	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole
prop:vtxr:828	Sensitivity	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole
prop:vtxr:829	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole
prop:vtxr:836	Sensitivity	v::ROS1	Non-Small Cell Lung Cancer	Taletrectinib
prop:vtxr:837	Sensitivity	c-Met >= 50%	Lung Non-Squamous Non-Small Cell Carcinoma	Telisotuzumab Vedotin
prop:vtxr:838	Sensitivity	KRAS p.G12C	Low-Grade Serous Ovarian Cancer	Avutometinib, Defactinib
prop:vtxr:839	Sensitivity	KRAS p.G12V	Low-Grade Serous Ovarian Cancer	Avutometinib, Defactinib
prop:vtxr:840	Sensitivity	t(15;17)	APL with PML-RARA	Arsenic trioxide
prop:vtxr:841	Sensitivity	CD30 +	Mycosis Fungoides	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
prop:vtxr:842	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Paclitaxel, Trastuzumab
prop:vtxr:843	Sensitivity	BRAF p.V600E	Melanoma	Pembrolizumab
prop:vtxr:844	Sensitivity	BRAF p.V600K	Melanoma	Pembrolizumab
prop:vtxr:845	Sensitivity	BRAF p.V600E	Melanoma	Nivolumab
prop:vtxr:846	Sensitivity	BRAF p.V600K	Melanoma	Nivolumab
prop:vtxr:847	Sensitivity	CD30 +	Angioimmunoblastic T-Cell Lymphoma	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
prop:vtxr:848	Sensitivity	CD30 +	Peripheral T-Cell lymphoma, NOS	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
prop:vtxr:849	Sensitivity	EGFR Somatic variants	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
prop:vtxr:850	Sensitivity	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
prop:vtxr:851	Sensitivity	EGFR p.L858R	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
prop:vtxr:852	Sensitivity	EGFR p.T790M	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
prop:vtxr:853	Sensitivity	EGFR Exon 20 (Insertion)	Invasive Breast Carcinoma	Datopotamab deruxtecan
prop:vtxr:854	Sensitivity	ER positive, HER2-negative	Invasive Breast Carcinoma	Datopotamab deruxtecan
prop:vtxr:855	Sensitivity	HER2-negative, PR positive	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
prop:vtxr:856	Sensitivity	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Datopotamab deruxtecan
prop:vtxr:857	Sensitivity	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Sunvozertinib
prop:vtxr:858	Sensitivity	ERBB2 TKD activating variants	Lung Non-Squamous Non-Small Cell Carcinoma	Zongertinib
prop:vtxr:859	Sensitivity	ER positive, HER2-low	Invasive Breast Carcinoma	Trastuzumab deruxtecan
prop:vtxr:860	Sensitivity	HER2-low, PR positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan
prop:vtxr:861	Sensitivity	ER positive, HER2-low, PR positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan
prop:vtxr:862	Sensitivity	ER positive, HER2-ultralow	Invasive Breast Carcinoma	Trastuzumab deruxtecan
prop:vtxr:863	Sensitivity	HER2-ultralow, PR positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan
prop:vtxr:864	Sensitivity	ER positive, HER2-ultralow, PR positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan
prop:vtxr:865	Sensitivity	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Docetaxel, Nivolumab
prop:vtxr:866	Sensitivity	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab
prop:vtxr:867	Sensitivity	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab
prop:vtxr:868	Sensitivity	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab
prop:vtxr:869	Sensitivity	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab
prop:vtxr:870	Sensitivity	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
prop:vtxr:871	Sensitivity	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab
prop:vtxr:872	Sensitivity	PD-L1 (TAP) >= 5%	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Tislelizumab
prop:vtxr:873	Sensitivity	PD-L1 (TAP) >= 5%	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab
prop:vtxr:874	Sensitivity	H3-3A p.K28M	Diffuse Midline Glioma	Dordaviprone
prop:vtxr:875	Sensitivity	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Imlunestrant
prop:vtxr:876	Sensitivity	HER2-positive, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Trastuzumab, Tucatinib
prop:vtxr:877	Sensitivity	FLT3-ITD	Acute Myeloid Leukemia	Quizartinib
prop:vtxr:878	Sensitivity	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Quizartinib
prop:vtxr:879	Sensitivity	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Idarubicin, Quizartinib
prop:vtxr:880	Sensitivity	NPM1 p.W288Cfs*12	Acute Myeloid Leukemia	Ziftomenib
prop:vtxr:881	Sensitivity	ERBB2 TKD activating variants	Lung Non-Squamous Non-Small Cell Carcinoma	Sevabertinib
prop:vtxr:882	Sensitivity	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab deruxtecan
prop:vtxr:883	Sensitivity	NPM1 p.W288Cfs*12	Acute Myeloid Leukemia	Revumenib
prop:vtxr:884	Sensitivity	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab
prop:vtxr:885	Sensitivity	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab
prop:vtxr:886	Sensitivity	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab
prop:vtxr:887	Sensitivity	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab
prop:vtxr:888	Sensitivity	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
prop:vtxr:889	Sensitivity	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab
prop:vtxr:890	Sensitivity	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab
prop:vtxr:891	Sensitivity	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab
prop:vtxr:892	Sensitivity	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab
prop:vtxr:893	Sensitivity	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab
prop:vtxr:894	Sensitivity	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
prop:vtxr:895	Sensitivity	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab
prop:vtxr:896	Sensitivity	HER2-negative, PD-L1 (TAP) >= 1%	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Tislelizumab
prop:vtxr:897	Sensitivity	HER2-negative, PD-L1 (TAP) >= 1%	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab
prop:vtxr:898	Sensitivity	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Tislelizumab
prop:vtxr:899	Sensitivity	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab
prop:vtxr:900	Sensitivity	NPM1 p.W288Cfs*12	Acute Lymphoid Leukemia	Revumenib
prop:vtxr:901	Sensitivity	NPM1 p.W288Cfs*12	Burkitt Lymphoma	Revumenib
prop:vtxr:902	Sensitivity	NPM1 p.W288Cfs*12	Acute Leukemias of Ambiguous Lineage	Revumenib
prop:vtxr:903	Sensitivity	FGFR2::v	Cholangiocarcinoma	Futibatinib
prop:vtxr:904	Sensitivity	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Irinotecan
prop:vtxr:905	Sensitivity	PD-L1 (CPS) >= 1	Ovarian Epithelial Tumor	Paclitaxel, Pembrolizumab
prop:vtxr:906	Sensitivity	PD-L1 (CPS) >= 1	Ovarian Epithelial Tumor	Bevacizumab, Paclitaxel, Pembrolizumab
prop:vtxr:907	Sensitivity	PD-L1 (CPS) >= 1	High-Grade Serous Fallopian Tube Cancer	Paclitaxel, Pembrolizumab
prop:vtxr:908	Sensitivity	PD-L1 (CPS) >= 1	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Paclitaxel, Pembrolizumab
prop:vtxr:909	Sensitivity	PD-L1 (CPS) >= 1	Peritoneal Serous Carcinoma	Paclitaxel, Pembrolizumab
prop:vtxr:910	Sensitivity	PD-L1 (CPS) >= 1	Peritoneal Serous Carcinoma	Bevacizumab, Paclitaxel, Pembrolizumab
prop:vtxr:911	Sensitivity	EGFR TKD activating variants	Non-Small Cell Lung Cancer	Gefitinib
prop:vtxr:912	Sensitivity	VHL pathogenic variants	Renal Cell Carcinoma	Belzutifan
prop:vtxr:913	Sensitivity	VHL pathogenic variants	Central Nervous System Hemangioblastoma	Belzutifan
prop:vtxr:914	Sensitivity	VHL pathogenic variants	Pancreatic Neuroendocrine Tumor	Belzutifan
prop:vtxr:915	Sensitivity	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fruquintinib
prop:vtxr:916	Sensitivity	PD-L1 > 0%	Non-Small Cell Lung Cancer	Nivolumab
prop:vtxr:917	Sensitivity	PD-L1 > 0%	Non-Small Cell Lung Cancer	Carboplatin, Paclitaxel, Pembrolizumab
prop:vtxr:918	Sensitivity	HLA-A*02:01	Uveal Melanoma	Tebentafusp
prop:vtxr:919	Sensitivity	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin, Cyclophosphamide, Dacarbazine, Dexamethasone, Doxorubicin, Etoposide
prop:vtxr:920	Sensitivity	BRAF p.V600E	Differentiated Thyroid Gland Carcinoma	Dabrafenib, Trametinib
prop:vtxr:921	Sensitivity	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Aumolertinib
prop:vtxr:922	Sensitivity	EGFR p.L858R	Non-Small Cell Lung Cancer	Aumolertinib
prop:vtxr:923	Sensitivity	EGFR p.T790M	Non-Small Cell Lung Cancer	Aumolertinib
prop:vtxr:924	Sensitivity	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Camizestrant
prop:vtxr:925	Sensitivity	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Camizestrant, Palbociclib
prop:vtxr:926	Sensitivity	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Camizestrant, Ribociclib
prop:vtxr:927	Sensitivity	t(11;14)	Mantle Cell Lymphoma	Ibrutinib
prop:vtxr:928	Sensitivity	CCND1	Mantle Cell Lymphoma	Ibrutinib
prop:vtxr:929	Sensitivity	CD20 +	Follicular Lymphoma	Bendamustine, Obinutuzumab
prop:vtxr:930	Sensitivity	CD20 +	Follicular Lymphoma	Cyclophosphamide, Doxorubicin, Obinutuzumab, Prednisolone, Vincristine
prop:vtxr:931	Sensitivity	CD20 +	Follicular Lymphoma	Cyclophosphamide, Obinutuzumab, Prednisolone, Vincristine
prop:vtxr:932	Sensitivity	HER2-negative, PD-L1 (CPS) >= 5	Stomach Adenocarcinoma	Capecitabine, Nivolumab, Oxaliplatin
prop:vtxr:933	Sensitivity	HER2-negative, PD-L1 (CPS) >= 5	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Nivolumab, Oxaliplatin
prop:vtxr:934	Sensitivity	HER2-negative, PD-L1 (CPS) >= 5	Esophageal Adenocarcinoma	Capecitabine, Nivolumab, Oxaliplatin
prop:vtxr:935	Sensitivity	BCR::ABL1	Acute Lymphoid Leukemia	Daunorubicin, Dexamethasone, Imatinib, Methotrexate, Vincristine
prop:vtxr:936	Sensitivity	BCR::ABL1, CD20 +	Acute Lymphoid Leukemia	Daunorubicin, Dexamethasone, Imatinib, Methotrexate, Rituximab, Vincristine
prop:vtxr:937	Sensitivity	CD20 +	Acute Lymphoid Leukemia	Daunorubicin, Dexamethasone, Methotrexate, Rituximab, Vincristine
prop:vtxr:938	Sensitivity	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Quizartinib
prop:vtxr:939	Sensitivity	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
prop:vtxr:940	Sensitivity	HER2-negative, PD-L1 (CPS) >= 5	Stomach Adenocarcinoma	Fluorouracil, Nivolumab, Oxaliplatin